Veradermics Inc 2026年季度报告

FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-43097________________________________ Veradermics, Incorporated (Exact name of registrant as specified in its charter)________________________________ Delaware84-3304423 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) (Address of Principal Executive Offices)(Zip Code) Registrant’s telephone number, including area code:(228) 372 3376 Name of each exchange on which registered New York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant wasrequired to file such reports), and (2) has been subject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for suchshorter period that the registrant was required to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of theExchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNo The number of shares of Registrant’s Common Stock outstanding as ofMay07, 2026 was 41,778,687. PART I - FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial Statements (unaudited)7Condensed Consolidated Balance Sheets (unaudited)7Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)9Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock andStockholders’ Equity (Deficit) (unaudited)10Condensed Consolidated Statements of Cash Flows (unaudited)12Notes to Financial Statements (unaudited)13Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations23Item 3.Quantitative and Qualitative Disclosure About Market Risk34Item 4.Controls and Procedures34 PART II - OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits 36369191919192 Signatures94 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that are based on management’s beliefs andassumptions and on information currently available to management. All statements other than statements of historical factscontained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,”“contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions,although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to,statements concerning: the initiation, timing, enrollment, progress, results, and cost of our research and development programs, and our currentand future preclinical and clinical studies, including statements regarding the timing of initiation or completion of ourclinical trials for VDPHL01 and our other product candidates, and related preparatory work, and the period during whichthe results of the trials will become available;our regulatory strategy and the timing of our planned NDA submission for VDPHL01;the success, cost and timing of our clinical development of VDPHL01 and our other product candidates;our ability to initiate, recruit and enroll patients in and conduct our clinical trials at the pace that we project;the timing of and our ability to obtain and maintain regulatory approval of our product candidates, and any relatedrestrictions, limitations or warnings in the label of any of our product candidates, if approved;our ability to compete with companies currently s